Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04228172 · ClinicalTrials.gov registry record
Genotypic Influences on Network Progression in Parkinson's Disease
A clinical trial of Parkinson's Disease, sponsored by Northwell Health.
- Active
- Registry status
- 32
- Enrollment target
- 1
- Study location
NCT04228172: Active study of Parkinson's Disease, sponsored by Northwell Health.
NCT04228172 is a study of Parkinson's Disease that is active but no longer recruiting, run by Northwell Health. The registered enrollment target is 32 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04228172, a study of Parkinson's Disease, is active but no longer recruiting, sponsored by Northwell Health.
- ACTIVE NOT RECRUITING
- Registry status
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
In this longitudinal study, the investigators will follow Parkinson's disease (PD) patients with and without glucocerebrosidase (GBA) mutations. The investigators hypothesize that the rate of increase in brain network activity over time (network progression rate) is faster in patients with GBA gene mutations.
Primary Outcome
Changes in PD related and PD cognition related pattern expression in 18F-2-fluoro-2-deoxy-D-glucose (FDG) PET scans
Conditions Studied
Interventions
- OTHER MRI scan
- GENETIC DNA/GeneticTesting
- RADIATION FDG PET scan
- OTHER Clinical and neuropsychological assessments
Study Locations (1)
New York
- Feinstein Institutes for Medical Research - Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-02-24 |
| Est. Completion | 2026-02-01 |
What the registry record for NCT04228172 still lists
NCT04228172 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 4 interventions - of which MRI scan is the first listed.
NCT04228172 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04228172 about?
NCT04228172 is a clinical study titled "Genotypic Influences on Network Progression in Parkinson's Disease". In this longitudinal study, the investigators will follow Parkinson's disease (PD) patients with and without glucocerebrosidase (GBA) mutations. The investigators hypothesize that the rate of increase in brain network activity over time (network progression rate) is faster in patients with GBA gene ...
What is the current status of trial NCT04228172?
This trial is currently active not recruiting. The enrollment target is 32 participants. The study started on 2020-02-24. Estimated completion is 2026-02-01.
What conditions does trial NCT04228172 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT04228172?
The interventions under investigation include: MRI scan (OTHER), DNA/GeneticTesting (GENETIC), FDG PET scan (RADIATION), Clinical and neuropsychological assessments (OTHER).
Who is sponsoring clinical trial NCT04228172?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04228172 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04228172's enrollment target sits among peer trials
32 101st of 158 higher than 55 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease
RECRUITING
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease
RECRUITING · NA
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI